Life Science Nation Newsletter  |  October 1, 2015  |  Issue 131

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Accelerator
Life Science Investor Mandates (Sept. 24 - Sept. 30)
Seeks East/West Life Science Opportunities
Invests In PMA & 510(k) Devices and Diagnostics
Seeks Oncology Assets
Seeks Pain, Neuromodulation and Orthopedic Technologies
In This Issue
September Mandate Roundup: Asian Based Investors Continue to Show Interest in Global Technologies

   READ MORE
Biotech Investor Trend: Combination Therapies

       READ MORE
RESI Boston Preclinical & Phase I Investors Panel

       READ MORE
LSN Videos
RESI Boston 2015 Diagnostic Investors Panel

Video Recap of RESI@TMCx 2015

September Mandate Roundup: Asian Based Investors Continue to Show Interest in Global Technologies
By Michael Quigley, Director of Research, LSN

This September, LSN's research staff managed to speak with and get mandates from 96 life science and healthcare investors from 15 countries all around the globe. As we have grown in the space over the past 3 years we are continuing to see more and more investors, particular from Asian countries like China (especially Hong Kong) and Taiwan with interests in investing in healthcare outside of their region.

Interestingly 75% of the mandates from Asia-based investors are looking for emerging technologies either globally, or to the US in addition to their local geographies. This is a trend that we have commented on in the past, and are seeing continue to grow and materialize as we speak with more and more investors...

  READ MORE  
  
  
Biotech Investor Trend: Combination Therapies
By Lucy Parkinson, Senior Research Manager, LSN    

LSN Research keeps in regular ongoing dialogue with 900 active life science investors and tracks an additional 4000 global investors. Those conversations often bring to light new trends that are on the minds of investors as they identify their mandate priorities. Recently, we've heard several investors express an interest in companies that could potentially use their asset as part of a combination therapy.

Combination therapies are currently a hot topic in biotech, although the approach has long been borne out in some disease areas, such as HIV HAART combinations and many cancer treatments. By using two drugs that interact favorably, one can affect a disease via multiple routes that may produce a powerful effect when combined. However, in the past these combinations have often been uncovered after a drug has been developed; by uncovering potential combination uses for an asset earlier in the development process, a biotech startup can increase the value of their asset. Investors are taking notice of this opportunity to add extra value to their portfolios...

   READ MORE   
RESI Boston Preclinical & Phase I Investors Panel
By Christine A. Wu, Research Analyst, LSN   

At our RESI Boston two weeks ago, Preclinical/Phase I stage investors joined us on a panel discussing their approach in seeking new early-stage deals, what they look for, and their process and advice for entrepreneurs.

Moderated by Steven Gullans, Managing Director, Excel Venture Management, our panelists include:
  • Arjun Goyal, Associate, 5AM Ventures
  • Sam Hall, Principal, Apple Tree Partners
  • Isai Peimer, Managing Director, MedImmune Ventures
  • Jayson Punwani, Principal, Pappas Ventures
The panel opened up saying that the industry is built on trust. Trust in partnering within their network, along with trust in developing relationships with their portfolio companies in terms of their management teams, their quality of science, and their clinical regulatory pathway potential...

   READ MORE